Recent news reports have linked the human papillomavirus (HPV) vaccine to serious adverse events (AEs) in children and adolescents. We used the Vaccine Adverse Event Reporting System (VAERS) database to extract postmarketing AEs reported in patients who received the vaccine. Since approval of the HPV vaccine in the US, 3174 AEs occurring in children and adolescents (aged 6-17 y) have been reported to the VAERS. Of these, 191 (6%) were deemed to be serious. Although these AEs are of significant concern, more research is required before they can be directly correlated with the vaccine.
Quadrivalent human papillomavirus vaccine: recommendation of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2007;56:1–24.
2.
DunneEF, UngerER, SternbergM. Prevalence of HPV infection among females in the United States. JAMA2007;297:813–9.
3.
American Academy of Pediatrics.Prevention of human papillomavirus infection: provisional recommendations for immunization of females with quadrivalent human papillomavirus vaccine. www.cispimmunize.org/ill/pdf/HPVprovisional.pdf (accessed 2008 Jul 24).
4.
CNN: Health news. Complaints cause cervical cancer vaccine scrutiny. www.cnn.com/health (accessed 2008 Jul 7).
5.
WestenJH. Deaths associated with the HPV vaccine start rolling in, over 3500 adverse events reported. September 20, 2007. www.lifesitenews.com/Idn/2007/sep/07092004.hml (accessed 2008 Jul 25).
6.
GarlandSM, Hernandez-AvilaM, WheelerCM. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med2007;356:1928–43.
7.
KoutskyLA, VillaLL, PerezG. Quadrivalent vaccine against human papillomavirus to prevent high grade cervical lesions. N Engl J Med2007;356:1915–27.
8.
BlockSL, NolanT, SattlerC. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics2006;118:2135–45.
9.
ReisingerKS, BlockSL, Lazcano-PonceE. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents. Pediatr Infect Dis J2007;26:201–9.
10.
VillaLL, CostaRR, PettaCA. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicenter phase II efficacy trial. Lancet Oncol2005;6:271–8.
